Evidence map›Paper›PMID 30079443›Full record

ReviewInvestigational new drugs2018

Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Chongchong Wang, Juehua Jing, Li Cheng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Investigational new drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The circular RNA circCRIM1 inhibits osteosarcoma progression through sponging miR-513.Mammalian genome : official journal of the International Mammalian Genome Society · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Chongchong WangDepartment of Oncology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.
Juehua JingDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. jjhhu@sina.com.
Li ChengDepartment of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, Anhui, China. chengli7788@163.com.
Anhui Medical University · CNSecond Hospital of Anhui Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-coding RNAs (ncRNAs) have been found to play essential roles in various physiological and pathological processes. The involvement of ncRNAs in the development of osteosarcoma (OS) has been explored in recent years. In this review, we summarize the functions and mechanisms of microRNA, lncRNA and circRNA in the initiation and progression of OS. We specifically focused on their potential application in the diagnosis, prognosis and therapy of OS. This summary of current knowledge on the involvement of ncRNAs in OS will not only aid comprehension of the complex processes of OS initiation and progression but also contribute to the exploration of ideal diagnostic biomarkers and therapeutic targets for OS patients.

Indexed as

Drug Resistance, NeoplasmEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansOsteosarcomaPrognosisRNA, UntranslatedRNA, UntranslatedcircRNAsLong non-coding RNAsmicroRNAsOsteosarcoma

Identifiers

PMID30079443
OpenAlexW2887222608

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.